


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app12.us.archive.org';v.server_ms=1360;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180713033521im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180713033521im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180713033521im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180713033521im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180713033521/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180713033521im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180713033521cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180713033521js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180713033521if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713033521/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180713033521if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713033521/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180713033521/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180713033521/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180713033521/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180713033521/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180713033521/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180713033521/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180713033521/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180713033521/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180713033521/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180713033521/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180713033521/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180713033521/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180713033521/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180713033521/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180713033521/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180713033521/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180713033521/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180713033521/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180713033521/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180713033521/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180713033521/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180713033521/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180713033521/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180713033521/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:009976</li>
            <li>2013 Jul 30
            </li>            
                                </ul>
        <div>
                <h1>Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180713033521/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20Academy%20of%20Neurology&amp;fLockTerm=American%2BAcademy%2Bof%2BNeurology">American Academy of Neurology</a></li>
                        <li>   
                                <a id="39" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30;81(5):463-9. [40 references] <a href="https://web.archive.org/web/20180713033521/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23897874" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.aan.com%252fGuidelines%252f">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180713033521/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180713033521/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180713033521/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180713033521/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180713033521/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180713033521/https://www.guideline.gov/search?f_ICD9CM_CUI=C0477355&amp;fLockTerm=Unspecified+extrapyramidal+disease+and+abnormal+movement+disorder">Unspecified extrapyramidal disease and abnormal movement disorder</a>
 (333.90)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0000981&amp;fLockTerm=Acetazolamide">Acetazolamide</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0002403&amp;fLockTerm=Amantadine">Amantadine</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0003402&amp;fLockTerm=Antioxidants">Antioxidants</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0040615&amp;fLockTerm=Antipsychotic+Agents">Antipsychotic Agents</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0005064&amp;fLockTerm=Benzodiazepines">Benzodiazepines</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0005578&amp;fLockTerm=Biperiden">Biperiden</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0006055&amp;fLockTerm=Botulinum+Toxins">Botulinum Toxins</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0006462&amp;fLockTerm=Buspirone">Buspirone</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0006684&amp;fLockTerm=Calcium+Channel+Blockers">Calcium Channel Blockers</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0242893&amp;fLockTerm=Cholinergic+Agents">Cholinergic Agents</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0242897&amp;fLockTerm=Cholinergic+Antagonists">Cholinergic Antagonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0009079&amp;fLockTerm=Clozapine">Clozapine</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0394162&amp;fLockTerm=Deep+Brain+Stimulation">Deep Brain Stimulation</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0012029&amp;fLockTerm=Dibenzazepines">Dibenzazepines</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0178601&amp;fLockTerm=Dopamine+Agonists">Dopamine Agonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0242702&amp;fLockTerm=Dopamine+Antagonists">Dopamine Antagonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0013806&amp;fLockTerm=Electroconvulsive+Therapy">Electroconvulsive Therapy</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0016367&amp;fLockTerm=Flupenthixol">Flupenthixol</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0242974&amp;fLockTerm=GABA+Agonists">GABA Agonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0018546&amp;fLockTerm=Haloperidol">Haloperidol</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0025741&amp;fLockTerm=Methyldopa">Methyldopa</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0026388&amp;fLockTerm=Molindone">Molindone</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0026650&amp;fLockTerm=Movement+Disorders">Movement Disorders</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0027741&amp;fLockTerm=Nerve+Block">Nerve Block</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0524850&amp;fLockTerm=Neurosurgical+Procedures">Neurosurgical Procedures</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0031436&amp;fLockTerm=Phenothiazines">Phenothiazines</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0031977&amp;fLockTerm=Piracetam">Piracetam</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0035179&amp;fLockTerm=Reserpine">Reserpine</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0073393&amp;fLockTerm=Risperidone">Risperidone</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0038803&amp;fLockTerm=Sulpiride">Sulpiride</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0686347&amp;fLockTerm=Tardive+Dyskinesia">Tardive Dyskinesia</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MSH_CUI=C0039623&amp;fLockTerm=Tetrabenazine">Tetrabenazine</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0000981&amp;fLockTerm=Acetazolamide">Acetazolamide</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0242896&amp;fLockTerm=Anticholinergic+Agents">Anticholinergic Agents</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0003402&amp;fLockTerm=Antioxidants">Antioxidants</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0005064&amp;fLockTerm=Benzodiazepines">Benzodiazepines</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0006055&amp;fLockTerm=Botulinum+Toxins">Botulinum Toxins</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0006684&amp;fLockTerm=Calcium+Channel+Blockers">Calcium Channel Blockers</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0242897&amp;fLockTerm=Cholinergic+Antagonists">Cholinergic Antagonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0009079&amp;fLockTerm=Clozapine">Clozapine</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0394162&amp;fLockTerm=Deep+Brain+Stimulation">Deep Brain Stimulation</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0178601&amp;fLockTerm=Dopamine+Agonists">Dopamine Agonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0242702&amp;fLockTerm=Dopamine+Antagonists">Dopamine Antagonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0013806&amp;fLockTerm=Electroconvulsive+Therapy">Electroconvulsive Therapy</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0477355&amp;fLockTerm=Extrapyramidal+and+movement+disorders">Extrapyramidal and movement disorders</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0242974&amp;fLockTerm=GABA+Agonists">GABA Agonists</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0018546&amp;fLockTerm=Haloperidol">Haloperidol</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0377265&amp;fLockTerm=Levetiracetam">Levetiracetam</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0025741&amp;fLockTerm=Methyldopa">Methyldopa</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0026650&amp;fLockTerm=Movement+Disorders">Movement Disorders</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0524850&amp;fLockTerm=Neurosurgical+Procedures">Neurosurgical Procedures</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0031436&amp;fLockTerm=Phenothiazines">Phenothiazines</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0686347&amp;fLockTerm=Tardive+Dyskinesia">Tardive Dyskinesia</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_MTH_CUI=C0039623&amp;fLockTerm=Tetrabenazine">Tetrabenazine</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180713033521/https://www.guideline.gov/search?f_PDQ_CUI=C0018546&amp;fLockTerm=haloperidol">haloperidol</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_PDQ_CUI=C0377265&amp;fLockTerm=levetiracetam">levetiracetam</a>
, <a href="/web/20180713033521/https://www.guideline.gov/search?f_PDQ_CUI=C0171023&amp;fLockTerm=olanzapine">olanzapine</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0000981&amp;fLockTerm=Acetazolamide">Acetazolamide</a>
 (33664007), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0000981&amp;fLockTerm=Acetazolamide">Acetazolamide</a>
 (372709008), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002403&amp;fLockTerm=Amantadine">Amantadine</a>
 (372763006), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002403&amp;fLockTerm=Amantadine">Amantadine</a>
 (51361008), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040615&amp;fLockTerm=Anti-psychotic+agent">Anti-psychotic agent</a>
 (10784006), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040615&amp;fLockTerm=Anti-psychotic+agent">Anti-psychotic agent</a>
 (372482001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0242896&amp;fLockTerm=Anticholinergic+agent">Anticholinergic agent</a>
 (14601000), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0242896&amp;fLockTerm=Anticholinergic+agent">Anticholinergic agent</a>
 (373246003), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005578&amp;fLockTerm=Biperiden">Biperiden</a>
 (387359004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005578&amp;fLockTerm=Biperiden">Biperiden</a>
 (65041000), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006462&amp;fLockTerm=Buspirone">Buspirone</a>
 (387523009), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006462&amp;fLockTerm=Buspirone">Buspirone</a>
 (91452003), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006684&amp;fLockTerm=Calcium+channel+blocker">Calcium channel blocker</a>
 (373304005), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006684&amp;fLockTerm=Calcium+channel+blocker">Calcium channel blocker</a>
 (48698004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006055&amp;fLockTerm=Clostridium+botulinum+toxin+agent">Clostridium botulinum toxin agent</a>
 (11894001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006055&amp;fLockTerm=Clostridium+botulinum+toxin+agent">Clostridium botulinum toxin agent</a>
 (418236003), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0006055&amp;fLockTerm=Clostridium+botulinum+toxin+agent">Clostridium botulinum toxin agent</a>
 (419254007), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009079&amp;fLockTerm=Clozapine">Clozapine</a>
 (387568001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009079&amp;fLockTerm=Clozapine">Clozapine</a>
 (96221003), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0394162&amp;fLockTerm=Deep+brain+stimulation">Deep brain stimulation</a>
 (230861003), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0178601&amp;fLockTerm=Dopamine+agonist+product">Dopamine agonist product</a>
 (384952006), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0178601&amp;fLockTerm=Dopamine+agonist+product">Dopamine agonist product</a>
 (418222008), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0242702&amp;fLockTerm=Dopamine+receptor+antagonist">Dopamine receptor antagonist</a>
 (713493000), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0013806&amp;fLockTerm=Electroconvulsive+therapy">Electroconvulsive therapy</a>
 (23835007), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016367&amp;fLockTerm=Flupentixol">Flupentixol</a>
 (387567006), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016367&amp;fLockTerm=Flupentixol">Flupentixol</a>
 (96220002), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0018546&amp;fLockTerm=Haloperidol">Haloperidol</a>
 (10756001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0018546&amp;fLockTerm=Haloperidol">Haloperidol</a>
 (386837002), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0377265&amp;fLockTerm=Levetiracetam">Levetiracetam</a>
 (116076009), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0377265&amp;fLockTerm=Levetiracetam">Levetiracetam</a>
 (387000003), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025741&amp;fLockTerm=Methyldopa">Methyldopa</a>
 (373542000), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025741&amp;fLockTerm=Methyldopa">Methyldopa</a>
 (84078002), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026388&amp;fLockTerm=Molindone">Molindone</a>
 (372799001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026388&amp;fLockTerm=Molindone">Molindone</a>
 (61408004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026650&amp;fLockTerm=Movement+disorder">Movement disorder</a>
 (60342002), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0027741&amp;fLockTerm=Nerve+block">Nerve block</a>
 (56333001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0027741&amp;fLockTerm=Nerve+block">Nerve block</a>
 (64874008), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0171023&amp;fLockTerm=Olanzapine">Olanzapine</a>
 (108441004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0171023&amp;fLockTerm=Olanzapine">Olanzapine</a>
 (386849001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0524850&amp;fLockTerm=Operation+on+nervous+system">Operation on nervous system</a>
 (16545005), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0031977&amp;fLockTerm=Piracetam">Piracetam</a>
 (322998004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0031977&amp;fLockTerm=Piracetam">Piracetam</a>
 (395833008), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0035179&amp;fLockTerm=Reserpine">Reserpine</a>
 (387447004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0035179&amp;fLockTerm=Reserpine">Reserpine</a>
 (78379001), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0073393&amp;fLockTerm=Risperidone">Risperidone</a>
 (108386000), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0073393&amp;fLockTerm=Risperidone">Risperidone</a>
 (386840002), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0038803&amp;fLockTerm=Sulpiride">Sulpiride</a>
 (321506004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0038803&amp;fLockTerm=Sulpiride">Sulpiride</a>
 (395891007), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0039623&amp;fLockTerm=Tetrabenazine">Tetrabenazine</a>
 (323260004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0039623&amp;fLockTerm=Tetrabenazine">Tetrabenazine</a>
 (363581004), <a href="/web/20180713033521/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0076513&amp;fLockTerm=Thiopropazate">Thiopropazate</a>
 (74713003)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#394" class="section-mark">Regulatory Alert</a></li>
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/downloadcontent/ngc-9976?contentType=pdf" class="pdf">.PDF 111.7 kb</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/downloadcontent/ngc-9976?contentType=word" class="word">Word Document 306.3 kb</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/downloadcontent/ngc-9976?contentType=xml" class="xml">.XML 52.3 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180713033521/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713033521/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713033521/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180713033521/mailto:/?Subject=AHRQ: Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.&amp;body=https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Jul 30. [cited 2018 Jul 13]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021?format=enw">EndNote</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021?format=txt">Medlars</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021?format=ris">ProCite</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021">RefWorks</a></li>
                            <li><a href="/web/20180713033521/https://www.guideline.gov/summaries/citedownload/47021?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="47021" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="394" class="accordion-title section-394 is-active" role="tab" aria-expanded="true"><a href="#">Regulatory Alert</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">FDA Warning/Regulatory Alert</a></h3>
                    <p><div class="content_para"><p><strong>Note from the National Guideline Clearinghouse</strong>: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.</p>
<ul style="list-style-type: disc;">
    <li><a href="https://web.archive.org/web/20180713033521/http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm518710.htm" target="_blank" title="FDA Web site">August 31, 2016 &ndash; Opioid pain and cough medicines combined with benzodiazepines</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>: A U.S. Food and Drug Administration (FDA) review has found that the growing combined used of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects, including slowed or difficult breathing and deaths. FDA is adding Boxed Warnings to the drug labeling of prescription opioid pain and prescription opioid cough medicines and benzodiazepines. </li>
</ul></div></p>

            </div>
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions of the levels of the recommendations (<strong>A, B, C, U</strong>) and classification of the evidence (<strong>Class I-IV</strong>) are provided at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Is Withdrawal of Dopamine Receptor Blocking Agents (DRBAs) an Effective Tardive Syndrome (TDS) Treatment?</strong></span></p>
<p><strong>Conclusion and Recommendation</strong></p>
<p>Data are insufficient to support or refute TDS treatment by DRBA withdrawal (<strong>Level U</strong>).</p>
<p><strong>Clinical Context</strong></p>
<p>The American Psychiatric Association Task Force recommends antipsychotic withdrawal only in patients who can tolerate it. Despite limited evidence, clinical impression indicates that short-term withdrawal may worsen dyskinesias, whereas adding antipsychotics with stronger extrapyramidal symptoms can reduce TDS. Psychotic relapse predictors include younger age, higher baseline antipsychotic dosage, and shorter hospitalization.</p>
<p><span style="text-decoration: underline;"><strong>Does Switching from Typical to Atypical DRBAs Reduce TDS Symptoms?</strong></span></p>
<p><strong>Conclusion and Recommendation</strong></p>
<p>Data are insufficient to support or refute TDS treatment by changing to atypical antipsychotics (<strong>Level U, Class IV studies</strong>).</p>
<p><span style="text-decoration: underline;"><strong>What Is the Efficacy of Pharmacologic Agents in Treating TDS?</strong></span></p>
<p><strong>Acetazolamide and Amantadine</strong></p>
<p><em>Conclusions</em></p>
<p>Acetazolamide and thiamine reduced TDS in one Class III study. Amantadine reduced TDS when used conjointly with a neuroleptic during the first 7 weeks (<strong>1 Class II study, 2 Class III studies</strong>). </p>
<p><em>Recommendations</em></p>
<p>Data are insufficient to support or refute TDS treatment with acetazolamide and thiamine (<strong>Level U</strong>). Amantadine with neuroleptics may be considered to treat TDS for short-term use (<strong>Level C</strong>).</p>
<p><em>Clinical Context</em></p>
<p>Only flupentixol decanoate, chlorpromazine, haloperidol, trifluoperazine, and thioridazine were tested with amantadine in these studies. The efficacy of amantadine plus other neuroleptics in TDS treatment is unknown. Because safety data are unavailable concerning long-term use of only typical neuroleptics as TDS suppressive agents and because of these agents' propensity to cause TDS, the evidence suggests only potential efficacy short-term.</p>
<p><strong>First-Generation Antipsychotics</strong></p>
<p><em>Conclusions</em></p>
<p>Haloperidol possibly reduces TDS movements for up to 2 weeks (<strong>2 Class II studies, 1 Class III study</strong>) but is associated with increased akinetic-rigid syndrome (<strong>1 Class II study</strong>). Data are insufficient to support or refute the use of thiopropazate in reducing oral dyskinesia (<strong>1 Class III study</strong>).</p>
<p><em>Recommendations</em></p>
<p>Data are insufficient to support or refute the use of thiopropazate, molindone, sulpiride, fluperlapine, and flupenthixol in treating TDS (<strong>Level U</strong>).</p>
<p><em>Clinical Context</em></p>
<p>Although haloperidol and thiopropazate possibly reduce TDS, they are not recommended because of the competing risk of akinetic-rigid syndrome. Safety data are unavailable concerning long-term use of typical antipsychotics as TDS suppressive agents, and these drugs themselves can cause TDS; these significant risks outweigh the benefits of any short-term use of typical antipsychotics.</p>
<p><strong>Second-Generation Antipsychotics: Clozapine, Risperidone, Olanzapine, and Other Agents</strong></p>
<p><em>Conclusions</em></p>
<p>Data are conflicting regarding the use of clozapine (<strong>conflicting Class III studies</strong>). Risperidone (<strong>2 Class II studies, 1 Class III study</strong>) is probably effective in reducing tardive dyskinesia (TDD). Olanzapine is possibly effective in reducing TDD (<strong>2 Class III studies</strong>). The safety of risperidone and olanzapine as a TDS suppressant for use beyond 48 weeks has not been addressed.</p>
<p>There is no evidence to determine the efficacy of quetiapine, ziprasidone, aripiprazole, and sertindole in TDS treatment.</p>
<p><em>Recommendations</em></p>
<p>Because neuroleptic agents may themselves cause TDS and may mask its symptoms rather than treat it, these drugs cannot be recommended for TDS treatment (<strong>Level U</strong>). Caution is advised when using risperidone or olanzapine to reduce TDS.</p>
<p><strong>Electroconvulsive Therapy</strong></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to determine the efficacy of electroconvulsive therapy for TDD treatment (<strong>Level U</strong>).</p>
<p><strong>Dopamine-Depleting Agents: Tetrabenazine, Reserpine, and &alpha;-Methyldopa</strong></p>
<p><em>Conclusions</em></p>
<p>Tetrabenazine (TBZ) possibly reduces TDS symptoms (<strong>2 consistent Class III studies</strong>). One study (<strong>Class III</strong>) found reserpine and &alpha;-methyldopa effective in treating TDS.</p>
<p><em>Recommendations</em></p>
<p>TBZ may be considered in treating TDS (<strong>Level C</strong>). Data are insufficient to determine the efficacy of reserpine or &alpha;-methyldopa in treating TDS (<strong>Level U</strong>).</p>
<p><em>Clinical Context</em></p>
<p>TBZ reduces TDS symptoms; there is no evidence that long-term TBZ administration induces TDS, but it can cause parkinsonism.</p>
<p><strong>Dopamine Agonists</strong></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to support or refute the use of bromocriptine for TDS treatment (<strong>Level U</strong>).</p>
<p><strong>Cholinergic Drugs</strong></p>
<p><em>Conclusion</em></p>
<p>Galantamine is possibly ineffective in treating TDS (<strong>1 Class II study</strong>).</p>
<p><em>Recommendations</em></p>
<p>Galantamine might not be considered in treating TDS (<strong>Level C</strong>). Data are insufficient to determine the effectiveness of other cholinergic drugs in treating TDS (<strong>Level U</strong>).</p>
<p><strong>Anticholinergic Drugs</strong></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to determine the effectiveness of anticholinergic drugs in treating TDS (<strong>Level U</strong>).</p>
<p><strong>Biperiden (Akineton) Discontinuation</strong></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to determine the effectiveness of biperiden discontinuation in treating TDS (<strong>Level U, 1 Class III study</strong>).</p>
<p><strong>Antioxidants</strong></p>
<p><em>Conclusions and Recommendations</em></p>
<p>EGb-761 is probably useful in TDS treatment (<strong>1 Class I study</strong>), but data are limited to inpatients with schizophrenia (<strong>Level B</strong>).</p>
<p>Based on 4 Class II and numerous Class III studies, data are conflicting regarding vitamin E efficacy in treating TDS. Data are insufficient to determine the efficacy of vitamin E (<strong>Level U</strong>).</p>
<p>Based on 1 Class II study, eicosapentaenoic acid (EPA) is possibly ineffective in treating TDS and might not be considered (<strong>Level C</strong>).</p>
<p>Melatonin is possibly ineffective in treating TDS at a 2-mg/d dose (<strong>1 Class II study</strong>) but is possibly effective in treating TDS at a 10-mg/d dose (<strong>1 Class II study</strong>). Evidence regarding TDS treatment with melatonin is conflicting (<strong>Level U</strong>).</p>
<p>Data are insufficient to support or refute the use of other antioxidants, including vitamin B<sub>6</sub>, selegiline, and yi-gan san, in treating TDS (<strong>Level U</strong>).</p>
<p><strong><em>&gamma;</em>-Aminobutyric Acid (GABA) Agonists</strong></p>
<p><em>Conclusions and Recommendations</em></p>
<p>Based on 1 Class I study, clonazepam is probably effective in decreasing TDD symptoms short-term (approximately 3 months) and should be considered for short-term TDD treatment (<strong>Level B</strong>). Data are insufficient to support or refute baclofen use in treating TDD (<strong>Level U</strong>).</p>
<p><strong>Levetiracetam</strong></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to recommend levetiracetam as TDS treatment (<strong>Level U, 1 Class III study</strong>).</p>
<p><strong>Calcium Channel Blockers</strong></p>
<p><em>Conclusions and Recommendations</em></p>
<p>Data are insufficient to support or refute nifedipine use in treating TDD (<strong>Level U</strong>). Diltiazem probably does not reduce TDD and should not be considered as treatment (<strong>Level B, 1 Class I study</strong>).</p>
<p><strong>Buspirone</strong></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to support or refute buspirone use in treating TDD (<strong>Level U, 1 Class III study</strong>).</p>
<p><span style="text-decoration: underline;"><strong>Do Patients with TDS Benefit From Chemodenervation with Botulinum Toxin (BoNT)?</strong></span></p>
<p><strong>Conclusion and Recommendation</strong></p>
<p>Data are insufficient to support or refute BoNT use to treat TDS symptoms (<strong>Level U</strong>).</p>
<p><span style="text-decoration: underline;"><strong>Do Patients with TDS Benefit From Surgical Therapy?</strong></span></p>
<p><em>Conclusion and Recommendation</em></p>
<p>Data are insufficient to support or refute pallidal deep brain stimulation (DBS) use in treating TDS (<strong>Level U, Class IV studies</strong>).</p>
<p><span style="text-decoration: underline;"><strong>Definitions</strong></span>:</p>
<p><strong>Classification of Evidence for Therapeutic Articles</strong></p>
<p><strong>Class I</strong>: A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p>The following are also required:</p>
<ol style="list-style-type: lower-alpha;">
    <li>Concealed allocation </li>
    <li>Primary outcome(s) clearly defined </li>
    <li>Exclusion/inclusion criteria clearly defined </li>
    <li>Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias. </li>
    <li>For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*
    <ol style="list-style-type: decimal;">
        <li>The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority. </li>
        <li>The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose and dosage adjustments are similar to those previously shown to be effective). </li>
        <li>The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment. </li>
        <li>The interpretation of the results of the study is based upon a per protocol analysis that takes into account dropouts or crossovers. </li>
    </ol>
    </li>
</ol>
<p><strong>Class II</strong>: A randomized, controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criterion from a&ndash;e above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b&ndash;e above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p><strong>Class III</strong>: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.**</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II or III criteria including consensus or expert opinion.</p>
<p class="Note">*Note that numbers 1&ndash;3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III.</p>
<p class="Note">**Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).</p>
<p><strong>Classification of Recommendations</strong></p>
<p><strong>A</strong> = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)*</p>
<p><strong>B</strong> = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)</p>
<p><strong>C</strong> = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)</p>
<p><strong>U</strong> = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.</p>
<p class="Note">*In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome &gt;5 and the lower limit of the confidence interval is &gt;2).</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Tardive syndromes (TDS), including tardive dyskinesias (TDD)</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Neurology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To make evidence-based recommendations regarding management of tardive syndromes (TDS), including tardive dyskinesias (TDD), by addressing five questions:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>Is withdrawal of dopamine receptor blocking agents (DRBAs) an effective TDS treatment? </li>
    <li>Does switching from typical to atypical DRBAs reduce TDS symptoms? </li>
    <li>What is the efficacy of pharmacologic agents in treating TDS? </li>
    <li>Do patients with TDS benefit from chemodenervation with botulinum toxin (BoNT)? </li>
    <li>Do patients with TDS benefit from surgical therapy? </li>
</ol></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Adult patients presenting with tardive syndromes (TDS), including tardive dyskinesias (TDD)</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>Withdrawal of dopamine receptor blocking agents (DRBAs) </li>
    <li>Switching from typical to atypical DRBAs </li>
    <li>Pharmacological agents
    <ul style="list-style-type: disc;">
        <li>Acetazolamide </li>
        <li>Amantadine </li>
        <li>First-generation antipsychotics (haloperidol, thiopropazate, molindone, sulpiride, fluperlapine and flupenthixol) </li>
        <li>Second-generation antipsychotics (clozapine, risperidone, olanzapine, and other neuroleptic agents) </li>
        <li>Electroconvulsive therapy </li>
        <li>Dopamine-depleting agents (tetrabenazine [TBZ], reserpine, and &alpha;-methyldopa) </li>
        <li>Dopamine agonists </li>
        <li>Cholinergic drugs </li>
        <li>Anticholinergic drugs </li>
        <li>Biperiden (Akineton) discontinuation </li>
        <li>Antioxidants </li>
        <li>&gamma;-Aminobutyric acid (GABA) agonists </li>
        <li>Levetiracetam </li>
        <li>Calcium channel blockers </li>
        <li>Buspirone </li>
    </ul>
    </li>
    <li>Chemodenervation with botulinum toxin (BoNT) </li>
    <li>Surgical therapy (pallidal deep brain stimulation [DBS]) </li>
</ol>
<p class="Note"><strong>Note</strong>: Many of the interventions above have insufficient evidence to support or refute their use in treating tardive syndromes (TDS) or are not recommended (see the "Major Recommendations" field).</p></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><div class="content_para"><p>Improvement on objective clinical rating scales of tardive syndromes (TDS) severity (e.g., Abnormal Involuntary Movement Scale [AIMS])</p></div></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Hand-searches of Published Literature (Primary Sources)</p>
                    <p>Hand-searches of Published Literature (Secondary Sources)</p>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>PsycINFO, Ovid MEDLINE, EMBASE, Web of Science, and Cochrane were searched (1966&ndash;2011) (see appendices e-3&ndash;e-7 of the data supplement [see the "Availability of Companion Documents field"]). The search was supplemented using the bibliography of retrieved articles and panelists' knowledge and following the American Academy of Neurology's (AAN's) process manual. The authors included studies of the following tardive syndrome (TDS) treatments: neuroleptic withdrawal, anticholinergics, benzodiazepines, &beta;-blockers, calcium channel blockers, cholinergics, GABAergic compounds, neuroleptic medications (including dose reduction and cessation), non-neuroleptic compounds that affect the dopamine and noradrenaline systems, vitamin B6, and vitamin E. The preferred outcome measures are objective clinical rating scales of TDS severity (e.g., Abnormal Involuntary Movement Scale [AIMS]). Two panelists reviewed abstracts and titles for relevance.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Classification of Evidence for Therapeutic Articles</strong></p>
<p><strong>Class I</strong>: A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p>The following are also required:</p>
<ol style="list-style-type: lower-alpha;">
    <li>Concealed allocation </li>
    <li>Primary outcome(s) clearly defined </li>
    <li>Exclusion/inclusion criteria clearly defined </li>
    <li>Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias. </li>
    <li>For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*
    <ol style="list-style-type: decimal;">
        <li>The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority. </li>
        <li>The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose and dosage adjustments are similar to those previously shown to be effective). </li>
        <li>The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment. </li>
        <li>The interpretation of the results of the study is based upon a per protocol analysis that takes into account dropouts or crossovers. </li>
    </ol>
    </li>
</ol>
<p><strong>Class II</strong>: A randomized, controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criterion from a&ndash;e above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b&ndash;e above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p><strong>Class III</strong>: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.**</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II or III criteria including consensus or expert opinion.</p>
<p class="Note">*Note that numbers 1&ndash;3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III.</p>
<p class="Note">**Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Two panelists reviewed abstracts and titles for relevance and rated selected studies using the American Academy of Neurology (AAN) therapeutic classification scheme (see the "Rating Scheme for the Strength of the Evidence" field).</p>
<p>See Table e-1 in the data supplement for a summary of the evidence (see the "Availability of Companion Documents" field).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>Recommendations were linked to the evidence (see the "Rating Scheme for the Strength of the Recommendations" field). Disagreements regarding classification were resolved by consensus.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Classification of Recommendations</strong></p>
<p><strong>A </strong>= Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)*</p>
<p><strong>B</strong> = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)</p>
<p><strong>C</strong> = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)</p>
<p><strong>U</strong> = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.</p>
<p class="Note">*In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome &gt;5 and the lower limit of the confidence interval is &gt;2).</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>Drafts of the guideline have been reviewed by at least 3 American Academy of Neurology (AAN) committees, a network of neurologists, Neurology&reg; peer reviewers, and representatives from related fields.</p>
<p>The original guideline document was approved by the Guideline Development Subcommittee on January 21, 2012; by the Practice Committee on October 1, 2012; and by the AAN Board of Directors on April 25, 2013.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate medical and surgical management of patients with tardive syndromes (TDS) </p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>Some of the drugs described in the guideline may have serious side effects or other risks associated with them. Refer to the "Major Recommendations" field and the original guideline document for specific recommendations and clinical context.</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>This statement is provided as an educational service of the American Academy of Neurology (AAN). It is based on an assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurologic problem or all legitimate criteria for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved. The clinical context section is made available in order to place the evidence-based guideline(s) into perspective with current practice habits and challenges. Formal practice recommendations are not intended to replace clinical judgment.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Patient Resources</p>
                    <p>Quick Reference Guides/Physician Guides</p>
                    <p>Resources</p>
                    <p>Slide Presentation</p>
                    <p>Staff Training/Competency Material</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30;81(5):463-9. [40 references] <a href="https://web.archive.org/web/20180713033521/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23897874" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: the guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2013 Jul 30</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>American Academy of Neurology - Medical Specialty Society</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>American Academy of Neurology (AAN)</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Guideline Development Subcommittee of the American Academy of Neurology</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Guideline Authors</em>: Roongroj Bhidayasiri, MD, FRCP; Stanley Fahn, MD, FAAN; William J. Weiner, MD, FAAN; Gary S. Gronseth, MD, FAAN; Kelly L. Sullivan, PhD; Theresa A. Zesiewicz, MD, FAAN</p>
<p><em>2011&ndash;2013 American Academy of Neurology Guideline Development Subcommittee (GDS) Members</em>: John D. England, MD, FAAN (<em>Chair</em>); Cynthia Harden, MD (<em>Vice-Chair</em>); Melissa Armstrong, MD; Eric Ashman, MD; Misha-Miroslav Backonja, MD; Richard L. Barbano, MD, PhD, FAAN; Diane Donley, MD; Terry Fife, MD, FAAN; David Gloss, MD; John J. Halperin, MD, FAAN; Cheryl Jaigobin, MD; Andres M. Kanner, MD; Jason Lazarou, MD; Steven R. Mess&eacute;, MD, FAAN; David Michelson, MD; Pushpa Narayanaswami, MD, MBBS; Anne Louise Oaklander, MD, PhD, FAAN; Tamara Pringsheim, MD; Alexander Rae-Grant, MD; Michael Shevell, MD, FAAN; Theresa A. Zesiewicz, MD, FAAN; Jonathan P. Hosey, MD, FAAN (<em>Ex-Officio</em>); Stephen Ashwal, MD, FAAN (<em>Ex-Officio</em>); Deborah Hirtz, MD, FAAN (<em>Ex-Officio</em>)</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p><strong>Conflict of Interest</strong></p>
<p>The American Academy of Neurology (AAN) is committed to producing independent, critical, and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the AAN keeps separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN limits the participation of authors with substantial conflicts of interest. The AAN forbids commercial participation in, or funding of, guideline projects. Drafts of the guideline have been reviewed by at least 3 AAN committees, a network of neurologists, <em>Neurology</em>&reg; peer reviewers, and representatives from related fields. The AAN Guideline Author Conflict of Interest Policy can be viewed at <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.aan.com" title="AAN Web site">www.aan.com</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p><strong>Disclosures</strong></p>
<p>R. Bhidayasiri is supported by the Rachadaphiseksomphot Endowment Fund part of the "Strengthen CUs Researchers Project" and research unit grant number GRU 52-026-30-005 of Chulalongkorn University, Bangkok, Thailand.</p>
<p>S. Fahn reports no disclosures.</p>
<p>W. Weiner is deceased; disclosures are not included for this author.</p>
<p>G. Gronseth and K. Sullivan report no disclosures.</p>
<p>T. Zesiewicz has received research funding from Boehringer-Ingelheim, Novartis, GlaxoSmithKline, Teva Neuroscience, General Electric, UCB Pharma, and the Friedreich's Ataxia Research Alliance.</p>
<p>Go to <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3a%2f%2fNeurology.org" title="Neurology Web site">Neurology.org</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> for full disclosures.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Electronic copies: A list of American Academy of Neurology (AAN) guidelines, along with a link to a Portable Document Format (PDF) file for this guideline, is available at the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.aan.com%2fGuidelines%2f" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>Print copies: Available from the AAN Member Services Center, (800) 879-1960, or from AAN, 201 Chicago Avenue South, Minneapolis, MN 55415.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Evidence-based guideline: treatment of tardive syndromes. Data supplement (e-appendices, e-references, e-table). St. Paul (MN): American Academy of Neurology; 2013. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3a%2f%2fneurology.org%2fcontent%2f81%2f5%2f463%2fsuppl%2fDC1" title="American Academy of Neurology (AAN) Web site">American Academy of Neurology (AAN) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Evidence-based guideline: treatment of tardive syndromes. Slide presentation. St. Paul (MN): American Academy of Neurology; 2013. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f616" title="American Academy of Neurology (AAN) Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Evidence-based guideline: treatment of tardive syndromes. AAN summary of evidence-based guideline for clinicians. St. Paul (MN): American Academy of Neurology. 2013; 3 p. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f613" title="American Academy of Neurology (AAN) Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Evidence-based guideline: treatment of tardive syndromes. Case study. St. Paul (MN): American Academy of Neurology. 2013; 7 p. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f615" title="American Academy of Neurology (AAN) Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Evidence-based guideline: treatment of tardive syndromes. Podcast. St. Paul (MN): American Academy of Neurology; 2013. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.neurology.org%2fcontent%2f81%2f5%2f463%2fsuppl%2fDC2" title="American Academy of Neurology (AAN) Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>AAN guideline development process [online]. St. Paul (MN): American Academy of Neurology. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fDevelopment" title="American Academy of Neurology (AAN) Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Treating and managing tardive syndromes. Summary of evidence-based guideline for patients and their families. St. Paul (MN): American Academy of Neurology. 2013. 3 p. Electronic copies: Available from the <a href="/web/20180713033521/https://www.guideline.gov/Home/Disclaimer?id=47021&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f614" title="American Academy of Neurology (AAN) Web site">American Academy of Neurology (AAN) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033521im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul>
<p class="Disclaimer">Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This summary was completed by ECRI Institute on November 18, 2013. This summary was updated by ECRI Institute on May 24, 2016 following the U.S. Food and Drug Administration advisory on Olanzapine. This summary was updated by ECRI Institute on May 31, 2016 following the U.S. Food and Drug Administration advisory on Aripiprazole (Abilify, Abilify Maintena, Aristada). This summary was updated by ECRI Institute on October 21, 2016 following the U.S. Food and Drug Administration advisory on opioid pain and cough medicines combined with benzodiazepines.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the American Academy of Neurology.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180713033521/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180713033521/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180713033521/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033521/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033521/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033521/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033521/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033521/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180713033521/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180713033521/https://www.guideline.gov/disclaimer?id=47021&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180713033521/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180713033521/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180713033521/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180713033521/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180713033521/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180713033521/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180713033521/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180713033521/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180713033521/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180713033521/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180713033521/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180713033521/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180713033521/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180713033521/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180713033521im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180713033521/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180713033521/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180713033521js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180713033521js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 03:35:21 Jul 13, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 16:51:40 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 1282.989 (3)
  esindex: 0.007
  captures_list: 1299.724
  CDXLines.iter: 12.557 (3)
  PetaboxLoader3.datanode: 88.88 (4)
  exclusion.robots: 0.211
  exclusion.robots.policy: 0.195
  RedisCDXSource: 1.013
  PetaboxLoader3.resolve: 1179.963
  load_resource: 40.21
-->